These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11459443)

  • 1. Analyzing counts, durations, and recurrences in clinical trials.
    McIntosh J
    J Biopharm Stat; 2001; 11(1-2):65-74. PubMed ID: 11459443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poisson regression analysis in clinical research.
    Kianifard F; Gallo PP
    J Biopharm Stat; 1995 Mar; 5(1):115-29. PubMed ID: 7613557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general family of distributions for longitudinal dependence with special reference to event histories.
    Lindsey JK
    Stat Med; 2001 Jun; 20(11):1625-38. PubMed ID: 11391692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Count data distributions and their zero-modified equivalents as a framework for modelling microbial data with a relatively high occurrence of zero counts.
    Gonzales-Barron U; Kerr M; Sheridan JJ; Butler F
    Int J Food Microbiol; 2010 Jan; 136(3):268-77. PubMed ID: 19913934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.
    Byar D; Blackard C
    Urology; 1977 Dec; 10(6):556-61. PubMed ID: 414402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling zero-inflated count data when exposure varies: With an application to tumor counts.
    Baetschmann G; Winkelmann R
    Biom J; 2013 Sep; 55(5):679-86. PubMed ID: 24003010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonparametric methods for analyzing incomplete nondecreasing repeated measurements.
    Davis CS; Wei LJ
    Biometrics; 1988 Dec; 44(4):1005-18. PubMed ID: 3148333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
    Cook RJ; Wei W
    Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
    Cancer Res; 1977 Aug; 37(8 Pt 2):2916-7. PubMed ID: 406040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of postoperative recurrence of bladder cancer: a clinical study].
    Yang D; Li S; Wang H; Li X; Liu S; Han W; Hao J; Zhang H
    Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):464-5. PubMed ID: 11829890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy.
    Nseyo UO
    Urol Clin North Am; 1992 Aug; 19(3):591-9. PubMed ID: 1386168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical treatment with thiotepa: an update review.
    Fosså SD
    Prog Clin Biol Res; 1984; 162B():163-8. PubMed ID: 6438640
    [No Abstract]   [Full Text] [Related]  

  • 14. On the use of zero-inflated and hurdle models for modeling vaccine adverse event count data.
    Rose CE; Martin SW; Wannemuehler KA; Plikaytis BD
    J Biopharm Stat; 2006; 16(4):463-81. PubMed ID: 16892908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of pairs of survival curves under heterogeneity: a Poisson correlated gamma-frailty approach.
    Fiocco M; Putter H; van Houwelingen JC
    Stat Med; 2009 Dec; 28(30):3782-97. PubMed ID: 19899066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
    Koontz WW; Heney NM; Soloway MS; Kluskens L; Hazra TA; Trump DL; Barton B
    Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
    Goebell PJ; Otto T; Suhr J; Rübben H
    J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whither thiotepa (for patients in the USA)?
    Dardis C; Milton K; Ashby L
    J Neurooncol; 2015 Sep; 124(3):529-30. PubMed ID: 26209975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.